Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CORINNE M HOWINGTON

Allopathic & Osteopathic Physicians Dermatology

NPI
1952392409
CMS profile
361628
Location
SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,164.94

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,164.94 67

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CORINNE M HOWINGTON

NPI 1952392409 · CMS profile ID 361628

Allopathic & Osteopathic Physicians / Dermatology

SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952392409?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CORINNE M HOWINGTON, NPI 1952392409, CMS profile ID 361628. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952392409?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CORINNE M HOWINGTON, NPI 1952392409, CMS profile ID 361628. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952392409?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CORINNE M HOWINGTON, NPI 1952392409, CMS profile ID 361628, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1952392409?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $1,164.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Galderma Laboratories, L.P. $13.6104/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855280583 CMS
AbbVie Inc. $13.1404/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794873297 CMS
AbbVie Inc. $1.3204/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794873301 CMS
Regeneron Healthcare Solutions, Inc. $18.0704/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809587813 CMS
Novartis Pharmaceuticals Corporation $20.2304/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812723171 CMS
Regeneron Healthcare Solutions, Inc. $19.1003/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809587811 CMS
AbbVie Inc. $16.7603/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794873293 CMS
Novartis Pharmaceuticals Corporation $15.9602/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812723169 CMS
Novartis Pharmaceuticals Corporation $24.9802/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812723163 CMS
AbbVie Inc. $17.4102/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794873289 CMS
Lilly USA, LLC $28.8902/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819029747 CMS
PFIZER INC. $17.0702/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832690829 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $14.3301/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851871375 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $11.6701/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849549389 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.7701/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851871377 CMS
Regeneron Healthcare Solutions, Inc. $19.3601/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809587809 CMS
AbbVie Inc. $17.6601/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794873285 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,643.27 105
PY2020 $1,919.90 62
PY2021 $1,164.94 67
PY2022 $1,557.52 73
PY2023 $1,758.03 83
PY2024 $1,676.33 77
PY2025 $2,016.21 97

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $164,999.10 28
PY2023 Principal investigator $24,126.96 8
PY2022 Principal investigator $88,836.33 14
PY2021 Principal investigator $44,079.52 10
PY2020 Recipient $15.63 1
PY2020 Principal investigator $331,834.61 38
PY2019 Recipient $5,653.36 2
PY2019 Principal investigator $207,960.93 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $2,655.00 10/09/2025 Non-covered Recipient Entity
ADVARRA INC
A Phase 3, Multi-Center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Subjects from 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246638883
Principal investigator 1 Amgen Inc. $4,664.93 06/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246649671
Principal investigator 1 Amgen Inc. $3,000.00 06/04/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246641211
Principal investigator 1 Amgen Inc. $4,144.01 04/24/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246638592
Principal investigator 1 Amgen Inc. $8,833.00 04/24/2025 Non-covered Recipient Entity
CLINICAL TRIALS RESEARCH
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246640395
Principal investigator 1 Amgen Inc. $1,685.00 04/24/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER CENTER OF LEES SUMMIT
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246640711
Principal investigator 1 Amgen Inc. $29,265.60 04/24/2025 Non-covered Recipient Entity
MEDICAL UNIVERSITY OFSOUTH CAROLINA
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246644266
Principal investigator 1 Amgen Inc. $6,567.77 04/24/2025 Non-covered Recipient Entity
RESEARCH FNDTN OF STATE UNIV OF NY
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246647219
Principal investigator 1 Amgen Inc. $19,136.00 04/24/2025 Non-covered Recipient Entity
SKIN RESEARCH OF SOUTH FLORIDA LLC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246648228
Principal investigator 1 Amgen Inc. $935.00 04/24/2025 Non-covered Recipient Entity
STUDIES IN DERMATOLOGY LLC LAUREN S CAMPBELL
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246648826
Principal investigator 1 Amgen Inc. $13,781.12 03/25/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246638072
Principal investigator 1 Amgen Inc. $15.33 03/25/2025 Non-covered Recipient Entity
CLEAR DERMATOLOGY
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246640265
Principal investigator 1 Amgen Inc. $347.02 03/25/2025 Non-covered Recipient Entity
FRONTIER DERM PARTNERS
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246641655
Principal investigator 1 Amgen Inc. $739.58 02/25/2025 Non-covered Recipient Entity
CIOCCA DERMATOLOGY
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246640233
Principal investigator 1 Amgen Inc. $24.53 02/25/2025 Non-covered Recipient Entity
CLINICAL SCIENCE INSTITUTE
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246640367
Principal investigator 1 Amgen Inc. $226.60 02/25/2025 Non-covered Recipient Entity
MEDDERM CORPORATION MEDDERM ASSOCIATES
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246644075
Principal investigator 1 Amgen Inc. $59.14 02/25/2025 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246644225
Principal investigator 1 Amgen Inc. $605.19 02/25/2025 Non-covered Recipient Entity
STUDIES IN DERMATOLOGY LLC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246648834
Principal investigator 1 Amgen Inc. $6,057.30 01/27/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246637674
Principal investigator 1 Amgen Inc. $10,395.95 01/27/2025 Covered Recipient Teaching Hospital
Henry Ford Hospital
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246637748
Principal investigator 1 Amgen Inc. $33,778.22 01/27/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246638372
Principal investigator 1 Amgen Inc. $481.23 01/27/2025 Non-covered Recipient Entity
BOESON RESEARCH
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246639761
Principal investigator 1 Amgen Inc. $487.66 01/27/2025 Non-covered Recipient Entity
CALIFORNIA DERMATOLOGY INSTITUTE
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246639851
Principal investigator 1 Amgen Inc. $204.34 01/27/2025 Non-covered Recipient Entity
HIGHTOWER CLINICAL LLC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246642284
Principal investigator 1 Amgen Inc. $9,782.67 01/27/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC PLLC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246643221
Principal investigator 1 Amgen Inc. $6,751.34 01/27/2025 Non-covered Recipient Entity
SOUTHERN INDIANA CLINICAL TRIALS
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246648477
Principal investigator 1 Amgen Inc. $189.24 01/27/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK, DOWNSTATE MEDICAL CENTER
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246648746
Principal investigator 1 Amgen Inc. $186.33 01/27/2025 Non-covered Recipient Entity
STRIDE CLINICAL RESEARCH LLC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246648794